Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) [Yahoo! Finance]
Dermata Therapeutics, Inc. (DRMA)
Company Research
Source: Yahoo! Finance
of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ACCESSWIRE / December 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it received approval from U.S. Food and Drug Administration (FDA) of the proprietary name, Xyngari (pronounced zin-gar-ee) (formerly DMT310), for its Phase 3 clinical drug candidate in acne. The proprietary name, Xyngari, is approved pending the successful submission and acceptance of a new drug application (NDA). "The FDA approving the Xyngari name is just one more successful step our team has completed in the development program for this unique product candidate," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "Having an approved proprietary name with the approaching Phase 3 acne topline
Show less
Read more
Impact Snapshot
Event Time:
DRMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRMA alerts
High impacting Dermata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DRMA
News
- AVAVA™ Announces Industry Heavyweights Clint Carnell as Executive Chairman and Mary Fisher to Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)Accesswire
- Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne [Yahoo! Finance]Yahoo! Finance
- Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of AcneAccesswire
- Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne [Yahoo! Finance]Yahoo! Finance
DRMA
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- 11/13/24 - Form 10-Q
- DRMA's page on the SEC website